StoryPartnership
Bristol Myers Squibb and BioNTech announce $11.1 billion BNT327 partnership
Bristol Myers Squibb and BioNTech entered a transformative partnership in June 2025 for BNT327. BMS provides $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028, with potential milestone payments up to $7.6 billion. The companies co-develop and co-commercialize the bispecific antibody globally, with profit and loss shared equally.